The current approach to screening for pre‐eclampsia is based on guidelines that rely on medical and obstetric history in early pregnancy to select a high‐risk group that might benefit from low‐dose aspirin. However, combined screening tests with the addition of biophysical and biochemical measurements have shown significantly better detection rates for preterm pre‐eclampsia. Furthermore, the administration of aspirin for the 10% screen‐positive group can lead to a significant reduction in severe and preterm forms of pre‐eclampsia. This review aims to answer frequently asked questions related to the clinical implementation of screening and the management of screening results.